Advisors Asset Management’s TG Therapeutics TGTX Stock Holding History

Advisors Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,600	Closed	-$181K	–	1535
2025 Q1	$181K	Sell	4,600 -2,378	-34%	-$80K	﹤0.01%	1124
2024 Q4	$210K	Hold	6,978	–	–	﹤0.01%	1111
2024 Q3	$163K	Hold	6,978	–	–	﹤0.01%	1142
2024 Q2	$124K	Sell	6,978 -16	-0.2%	-$255	﹤0.01%	1176
2024 Q1	$106K	Sell	6,994 -109	-2%	-$1.74K	﹤0.01%	1206
2023 Q4	$121K	Sell	7,103 -277	-4%	-$3.22K	﹤0.01%	1178
2023 Q3	$61.7K	Buy	7,380 +4,991	+209%	+$69.6K	﹤0.01%	1254
2023 Q2	$59.3K	Buy	+2,389	New	+$61.7K	﹤0.01%	1260

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Advisors Asset Management's TGTX Position: Q2 2025 in Review

Advisors Asset Management sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 4,600 shares — an estimated $181K sold.

Advisors Asset Management first reported a position in TGTX in Q2 2023 and held it in 8 quarters. The position peaked at $210K in Q4 2024. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

Advisors Asset Management reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
Advisors Asset Management sold 4,600 TG Therapeutics shares in Q2 2025, an estimated $181K.
Advisors Asset Management first reported a position in TG Therapeutics in Q2 2023 and held it in 8 quarters.
Advisors Asset Management's TG Therapeutics position peaked at $210K in Q4 2024.
356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Advisors Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.